Sam Brusco, Associate Editor05.17.24
Merit Medical Systems has appointed longtime veteran Joe Wright as the company’s new president, effective immediately.
Wright joined Merit Medical in 2005, serving in a variety of positions and most recently as chief commercial officer. Before this role, he was president of the company’s international division for business units in APAC and the Americas.
Prior to that, Wright was president of Merit Technology Group, heading Merit OEM, Merit Sensor, and MCTec B.V. He was also the VP of global marketing for Merit. He oversaw creation of Merit China in Beijing during his tenure and established Merit Asia in Hong Kong. Before joining Merit, Wright had sales, marketing, and business development roles in Motorola and Micron.
This news comes in the wake of CEO Lampropoulos’ announced retirement at the end of 2025. Merit’s board continues to identify internal and external CEO candidates, overseen by the company’s independent directors and executive search firm Korn Ferry.
“Investing in our people is a core part of the growth and profitability of our Continued Growth Initiatives Program,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “Joe has been central to executing our strategic plan and positioning the company for continued success, including spearheading our commercialization efforts and overseeing significant international expansion, engineering the advanced capabilities of our renal therapies group, including the integration of the business and assets we acquired from AngioDynamics in 2023, and directing the development of our commercial excellence initiatives globally. He is a valuable member of our leadership team, and I look forward to continuing to work closely with him to improve the lives of patients and drive sustained value creation for our shareholders.”
This news comes in the wake of CEO Lampropoulos’ announced retirement at the end of 2025. Merit’s board continues to identify internal and external CEO candidates, overseen by the company’s independent directors and executive search firm Korn Ferry.
“I am honored to take on the role of President at this important point in Merit’s journey,” added Wright. “I have been a part of this team for almost two decades and have developed a deep appreciation of Merit’s innovative technology, global access, unique and successful culture, alignment of values within the healthcare system and opportunities for growth. I look forward to advancing our CGI objectives, improving the profitability of our business, and investing in our future.”
Earlier this year, the company secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Scout MD surgical guidance system for breast and soft tissue cancers.
Wright joined Merit Medical in 2005, serving in a variety of positions and most recently as chief commercial officer. Before this role, he was president of the company’s international division for business units in APAC and the Americas.
Prior to that, Wright was president of Merit Technology Group, heading Merit OEM, Merit Sensor, and MCTec B.V. He was also the VP of global marketing for Merit. He oversaw creation of Merit China in Beijing during his tenure and established Merit Asia in Hong Kong. Before joining Merit, Wright had sales, marketing, and business development roles in Motorola and Micron.
This news comes in the wake of CEO Lampropoulos’ announced retirement at the end of 2025. Merit’s board continues to identify internal and external CEO candidates, overseen by the company’s independent directors and executive search firm Korn Ferry.
“Investing in our people is a core part of the growth and profitability of our Continued Growth Initiatives Program,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “Joe has been central to executing our strategic plan and positioning the company for continued success, including spearheading our commercialization efforts and overseeing significant international expansion, engineering the advanced capabilities of our renal therapies group, including the integration of the business and assets we acquired from AngioDynamics in 2023, and directing the development of our commercial excellence initiatives globally. He is a valuable member of our leadership team, and I look forward to continuing to work closely with him to improve the lives of patients and drive sustained value creation for our shareholders.”
This news comes in the wake of CEO Lampropoulos’ announced retirement at the end of 2025. Merit’s board continues to identify internal and external CEO candidates, overseen by the company’s independent directors and executive search firm Korn Ferry.
“I am honored to take on the role of President at this important point in Merit’s journey,” added Wright. “I have been a part of this team for almost two decades and have developed a deep appreciation of Merit’s innovative technology, global access, unique and successful culture, alignment of values within the healthcare system and opportunities for growth. I look forward to advancing our CGI objectives, improving the profitability of our business, and investing in our future.”
Earlier this year, the company secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Scout MD surgical guidance system for breast and soft tissue cancers.